Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
Eva Soler Espejo, Consultant Hematologist at Virgen de la Arrixaca University Clinical Hospital, shared a post on LinkedIn about a recent article she co-authored with her colleagues, adding:
”Anticoagulation in atrial fibrillation reduces risk — but does not eliminate it completely.
I am very pleased to share our latest publication in the Journal of the American Heart Association (JAHA).
In this prospective real-world study of anticoagulated patients with atrial fibrillation, we investigated whether the Atherogenic Index of Plasma (AIP) could help identify residual cardiovascular and thromboembolic risk.
Higher AIP levels were independently associated with worse clinical outcomes, particularly thromboembolic events and major adverse cardiovascular events (MACE), suggesting that this simple metabolic marker may provide incremental prognostic value beyond conventional risk assessment.
These findings underline the importance of better understanding residual risk in order to move towards more personalised and comprehensive management strategies in patients with AF.”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler‐Espejo, Yang Chen, José M. Rivera‐Caravaca, María P. Ramos‐Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on Journal of the American Heart Association
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!